Benefits of Permanent His Bundle Pacing Combined With Atrioventricular Node Ablation in Atrial Fibrillation Patients With Heart Failure With Both Preserved and Reduced Left Ventricular Ejection Fraction

Weijian Huang, MD; Lan Su, MD; Shengjie Wu, MD; Lei Xu, MD; Fangyi Xiao, MD; Xiaohong Zhou, MD; Kenneth A. Ellenbogen, MD

Background—Clinical benefits from His bundle pacing (HBP) in heart failure patients with preserved and reduced left ventricular ejection fraction are still inconclusive. This study evaluated clinical outcomes of permanent HBP in atrial fibrillation patients with narrow QRS who underwent atrioventricular node ablation for heart failure symptoms despite rate control by medication.

Methods and Results—The study enrolled 52 consecutive heart failure patients who underwent attempted atrioventricular node ablation and HBP for symptomatic atrial fibrillation. Echocardiographic left ventricular ejection fraction and left ventricular end-diastolic dimension, New York Heart Association classification and use of diuretics for heart failure were assessed during follow-up visits after permanent HBP. Of 52 patients, 42 patients (80.8%) received permanent HBP and atrioventricular node ablation with a median 20-month follow-up. There was no significant change between native and paced QRS duration (107.1±25.8 versus 105.3±23.9 milliseconds, P=0.07). Left ventricular end-diastolic dimension decreased from the baseline (P<0.001), and left ventricular ejection fraction increased from baseline (P<0.001) in patients with a greater improvement in heart failure with reduced ejection fraction patients (N=20) than in heart failure with preserved ejection fraction patients (N=22). New York Heart Association classification improved from a baseline 2.9±0.6 to 1.4±0.4 after HBP in heart failure with reduced ejection fraction patients and from a baseline 2.7±0.6 to 1.4±0.5 after HBP in heart failure with preserved ejection fraction patients. After 1 year of HBP, the numbers of patients who used diuretics for heart failure decreased significantly (P<0.001) when compared to the baseline diuretics use.

Conclusions—Permanent HBP post–atrioventricular node ablation significantly improved echocardiographic measurements and New York Heart Association classification and reduced diuretics use for heart failure management in atrial fibrillation patients with narrow QRS who suffered from heart failure with preserved or reduced ejection fraction. (J Am Heart Assoc. 2017;6:e005309. DOI: 10.1161/JAHA.116.005309.)

Key Words: atrial fibrillation • atrioventricular node ablation • heart failure • His bundle pacing

Multiple clinical studies have demonstrated improved quality of life following atrioventricular node (AVN) ablation and permanent right ventricular (RV) pacing in patients with symptomatic atrial fibrillation (AF) refractory to optimal medical therapy.1–4 However, several studies performed over the last decade have demonstrated that conventional long-term RV apical pacing can increase the risk of death and heart failure hospitalization.5–6 It is well known that long-term RV apical pacing produces wide QRS duration (QRSd), left ventricular (LV) dyssynchrony, hemodynamic impairment, negative inotropy, and LV diastolic and systolic dysfunction in a subgroup of pacemaker-dependent patients.4,7,8 Thus, other pacing sites as an alternative to RV apical pacing have been explored, although clinical benefits from alternative pacing sites are still inconclusive.9,10

The His-Purkinje conduction system allows the impulse generated by the sinoatrial node to rapidly propagate into both right and left ventricles and hence ensures synchronized ventricular contraction. An early study by El-Sherif...
et al demonstrated that distal His bundle pacing (HBP) could normalize bundle branch block and QRS morphology. In 2000, Deshmukh et al first successfully implemented permanent direct HBP in a small number of patients with AF and dilated cardiomyopathy and found improvements in LV dimensions and cardiac function. Since then, there have been multiple reports on HBP in patients who need pacemaker therapy including those with AVN ablation or heart failure or patients for conventional pacemaker therapy. Although cardiac resynchronization therapy (CRT) can be used in patients after AVN ablation, studies have shown no significant clinical benefits if patients have a narrow QRSd. On the other hand, following AVN ablation, HBP can provide physiological activation and hence avoids ventricular dyssynchrony and preserves ventricular function in patients with a narrow QRSd. The objective of the present study was to evaluate clinical outcomes of permanent HBP in patients with heart failure who also underwent AVN ablation with AF and to compare the difference between patients with reduced LV ejection fraction (LVEF; HFrEF) versus those with preserved LVEF (HFpEF).

Methods

The present study was a single-center prospective registry in heart failure patients who underwent AVN ablation and had long-standing persistent AF with rate control and received a pacemaker or implanted cardioverter-defibrillator or CRT device. The study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Wenzhou Medical University. All patients completed written informed consent.

Study Patients

Consecutive patients who met the inclusion criteria were enrolled between August 2012 and August 2015. The inclusion criteria were the following: (1) patients had symptomatic heart failure and long-lasting persistent or permanent AF even though their heart rate was controlled with pharmacological treatment during AF; (2) New York Heart Association (NYHA) classification was II or III; (3) patients had at least 1 heart failure–related hospitalization in the last 12 months despite optimal heart failure therapy; and (4) patients were at least 18 years old and not pregnant. The patients could present with either HFpEF or HFrEF. Patients with any of the following conditions were excluded: (1) intraventricular conduction block or delay on 12-lead ECG; (2) severe mitral or aortic valve regurgitation; (3) congenital heart disease requiring cardiac surgery; (4) chronic kidney disease with dialysis; and (5) severe chronic obstructive pulmonary disease.

Implantation Procedure

Lead Placement

Each patient underwent implantation procedures as described previously. Briefly, the delivery sheath (model C304 or C315, Medtronic, Inc, Minneapolis, MN) was inserted via the left axillary vein into the His bundle region in the atrioventricular (AV) septum superior to the tricuspid valve. The Select Secure™ lead (model 3830, Medtronic, Inc, Minneapolis, MN) that was used for His bundle pacing was advanced through the sheath, and only the distal part of the lead was extended beyond the tip of the sheath for a unipolar HBP. In a few patients when the pacing lead could not achieve HBP, a multielectrode mapping catheter was used to identify the His bundle potential, and then the Select Secure™ lead was used for HBP. An electrogram from the lead tip electrode along with 12-lead surface ECG was displayed and recorded (GE CardioLab EP Recording System 2000, GE Inc, Waukesha, WI). Once pacing parameters were acceptable, the Select Secure™ pacing lead was fixed. If HBP parameters were not adequate, the first Select Secure™ lead was left in place as a marker while the second Select Secure™ lead was inserted to identify an optimal His bundle location where HBP parameters were accepted. If dual leads were used, one lead was placed in the His bundle region for HBP while the other lead was positioned in the right RV for backup pacing.

His Bundle Pacing Testing

Once the His bundle potential was recorded in an electrogram, an HBP test was performed to measure pacing parameters and compare the intrinsic ECG QRS with the ECG QRS during HBP, which was similar to the criteria defined by Deshmukh et al. The morphology of ECG QRS-T waveform during HBP was similar to that during intrinsic rhythm, and the interval from the His-pacing artifact to the beginning of the paced ECG QRS was identical to the intrinsic His-QRS interval. A pacing output that was slightly higher than the HBP threshold that maintained 1:1 His-ventricular conduction at a rate of 140 beats/min was accepted. During HBP test, if direct His bundle pacing could not be obtained but para-Hisian pacing was obtained, para-Hisian pacing was accepted. Para-Hisian pacing was mainly characterized by the following: (1), the interval between the pacing artifact and ECG QRS at low pacing output was shorter than the intrinsic His-QRS interval, and (2) there was a similarity between the electrical axis of the paced QRS and that of the intrinsic QRS. In the present study, patients with direct HBP and para-Hisian pacing were pooled as 1 pacing group.

RV leads or LV leads were implanted in a standard fashion at the RV apex (or RV septum) or lateral cardiac vein, respectively. The HBP lead was connected to the device atrial port in 38 patients, in the LV port in 3 patients, and in the RV...
port in 1 patient. After all leads were positioned, the device was buried in the pocket. The lower rate for permanent HBP was initially set at 80 beats/min, then programmed to 70 beats/min at 1 to 3 months while backup RV or LV pacing was programmed at long AV intervals.

**Atrioventricular Node Ablation**

After HBP was established, an 8.5-F sheath (SR0 or SL1, St. Jude Medical Inc, St. Paul, MN) was inserted via the femoral vein to the supra-His bundle region (including AVN and nearby proximal His bundle) with a more than 8 mm distance from the HBP site, where the HBP lead was served as a marker (Figure 1). Complete AV block was achieved by radiofrequency ablation using a conventional quadripolar 7-Fr 4-mm-tip ablation catheter (Celsius, Biosense Webster Inc, Diamond Bar, CA) (N=24), or a Thermocool™ (N=8) or Thermocool SF™ (N=10) mapping/ablation catheter (Biosense Webster Inc, Diamond Bar, CA). Desired success of AVN ablation was evidenced with complete AV block without change in HBP parameters. Based on our experience, we proposed the following criteria: (1) complete AV block, (2) no changes in HBP threshold and His-ventricular conduction, and (3) the same morphology of QRS complex during HBP before and after AVN ablation. Isoprenaline infusion (at 20-40 μg/min) over 10 minutes was given to ensure no recurrence of AV conduction.

**Data Collection and Follow-Up**

Demographic and medical history was collected at enrollment. Baseline mean HR was determined by either 24-hour Holter recording or ECG monitoring during hospitalization. Device electrical performance, including sensed R-wave amplitude, pacing threshold, and percentage of HBP, was assessed at outpatient visits at week 1, and 1, 3, 6, and 12 months up to 36 months postimplantation. Lead-related complications including infection, dislodgement, loss of capture, and early battery depletion were also tracked. Clinical outcomes including echocardiography, cardiac function assessment (NYHA classification), mortality, hospitalization, and medication for heart failure were assessed at 3-month and annual follow-up visits after permanent HBP. Echocardiographic images were obtained in the standard parasternal long- and short-axis and apical 4-chamber and 2-chamber views using commercially available ultrasound equipment (Philips, iE Elite, Amsterdam, Netherlands). LVEF was obtained using the modified Simpson rule. All echocardiograms were assessed by an experienced echocardiographer who was blinded to the study design. The LV end-diastolic dimension was measured in the parasternal long-axis view. Mitral jet area as a percentage of left atrial area was used to assess the severity of mitral valve regurgitation, and the severity of tricuspid valve regurgitation was graded by the proportion of jet area in right atrial area.23 The severity of valve regurgitation was classified as 0, none; 1, mild; 2, moderate; 3, severe. Serum B-type natriuretic peptide (BNP) levels were measured before and after permanent HBP.

**Statistical Analyses**

Continuous variables were expressed with mean±SD if they met normal or similar to normal distribution, and paired t tests were performed to compare the differences between 2 time points, for example, the baseline and the specific time point

![Figure 1](image-url)  
**Figure 1.** Right (A) and left (B) anterior oblique fluoroscopic projections showing location of His bundle pacing lead and ablation catheter.
during HBP. Otherwise, a signed rank-sum test would be applied for the comparison between the baseline and the specific time point during HBP for an ordinal variable such as NYHA class and valve regurgitations. For echocardiographic LV end-diastolic dimension (LVEDd) and LVEF and device interrogated parameters (HBP threshold, sensed R-wave amplitude, and the percentage of HBP) that were collected at baseline and later multiple different time points, univariate analysis of variance for repeated measures (generalized linear model) was used to assess the effects of HBP, and post hoc tests with least significant difference were performed for the variables that showed a statistically significant difference. Categorical data were described as number (%), and the McNemar test was used to determine whether the difference between a specific time point and baseline on the proportion of patients who received medications reached statistically significant level. Pearson product-moment correlation coefficient was selected to explore the association between echocardiographic changes in LVEDd and LVEF after HBP versus their related baseline values. Stratified analyses in echocardiographic measurements, clinical assessments, and medications were also performed for the subgroups of patients with either HFrEF (LVEF ≤40%) or HFpEF (LVEF >40%). All data management and analysis were finished with SPSS version 20.0 (SPSS, Chicago, IL). All hypothesis tests were 2-tailed, and P value of ≤0.05 was set as statistically significant.

Results

Implantation Results and Patient Characteristics

In all 52 enrolled patients HBP and AVN ablation were attempted (Figure 2). His bundle potential was not recorded in 2 of these patients (3.8%). Acute HBP was achieved in the remaining 50 patients (96.2%). Of the 50 patients with successful acute HBP, 42 patients (80.8% of all patients for HBP attempts) received permanent HBP (38 with direct HBP and 4 with para-Hisian pacing; Figure 2), and 8 patients (15.4%) did not receive permanent HBP because of His bundle injury by ablation (N=2), failed AVN ablation (N=2), or resumption of AVN conduction (N=4, heart rate at 83.8±15.6 beats/min at 16.8±19.8 days after successful acute AVN ablation). Permanent HBP was implemented by a dual-chamber pacemaker in 17 patients, by CRT-pacemaker/CRT-defibrillator in 17 patients, and by a dual-chamber implanted cardioverter-defibrillator in 8 patients, all for ventricular backup pacing.

Baseline characteristics of the patients with permanent HBP are summarized in Table 1. Baseline QRSd was 107.1±25.8 milliseconds, and averaged heart rate under AF rate control therapy was 83.9±14.1 beats/min. Baseline averaged heart rate was 83.4±15.2 beats/min in patients with HFrEF and 84.3±13.7 beats/min in patients with HFpEF. Prior to the HBP implantation, patients underwent heart failure pharmacological therapy including β-blockers, angiotensin-converting enzyme inhibitor, and diuretics for a median 28 months before HBP. The mean follow-up period after HBP was 21.1±9.3 months (median 20 months).

Table 1. Patient Baseline Characteristics

| Parameters                  | Mean±SD or Percentage (Number) |
|-----------------------------|--------------------------------|
| Age, y                      | 72.8±8.3                       |
| Male                        | 61.9% (26)                     |
| Height, cm                  | 163.2±6.3                      |
| Weight, kg                  | 66.6±11.9                      |
| Heart rate, beats/min       | 83.9±14.1                      |
| QRS duration, milliseconds  |                                |
| Native QRS                  | 107.1±25.8                     |
| Paced QRS                   | 105.3±23.9                     |
| Hypertension                | 78.6% (33)                     |
| Coronary heart disease      | 28.6% (12)                     |
| PCI history                 | 19.0% (8)                      |
| Myocardial infarction       | 9.5% (4)                       |
| Stroke history              | 38.1% (16)                     |
| Diabetes mellitus           | 23.8% (10)                     |
| Kidney dysfunction          | 11.9% (5)                      |

PCI indicates percutaneous coronary intervention.
His Bundle Pacing at Implantation

Figure 3 shows an example of 12-lead surface ECG and 3830-lead recorded electrogram during implantation. The His-QRS interval during intrinsic AV conduction (Figure 3A and 3B) was identical to the HBP artifact-QRS interval (Figure 3C). The morphology of the ECG QRS complex during intrinsic AV conduction (Figure 3A and 3B) was identical to that of the intrinsic ECG QRS complex (Figure 3), suggesting identical activation sequences during intrinsic rhythm and His bundle pacing.

Acute HBP threshold was 1.5±1.0 V at a pulse width of 0.5±0.1 millisecond. QRSd was 107.1±25.8 milliseconds during intrinsic rhythm and 105.3±23.9 milliseconds during HBP (P=0.07 versus intrinsic QRSd). The intrinsic His-QRS interval was 54.7±10.4 milliseconds and was not significantly different from the HBP artifact-QRS interval (54.0±7.5 milliseconds, P=0.499 versus the intrinsic His-QRS interval).

Temporary right bundle branch block occurred in 8 cases, and third-degree AV block occurred in 2 cases during the His bundle lead implantation procedure. Seven of 8 cases with right bundle branch block and 2 cases of third-degree AV block fully recovered during implantation. After implantation, there was no lead dislodgement.

Echocardiographic Changes After His Bundle Pacing

Compared to baseline echocardiographic values that were measured a median of 8 days before the HBP procedure, LVEDd significantly decreased while LVEF increased after permanent HBP (Table 2). The improvements in LVEDd and LVEF were present at 3 months of HBP, and more improvement was observed over 1 year of HBP (Table 2). The degree of mitral valve regurgitation at 1-year follow-up visit was significantly reduced (1.0±0.7) when compared to the baseline value (1.3±0.9, P=0.013). There was no significant change in tricuspid valve regurgitation between the degree at baseline (1.5±0.9) and that at 1-year follow-up (1.4±1.0, P=0.510 versus the baseline). The magnitude of the improvement in LVEF and LVEDd was significantly correlated to the baseline severity of ventricular function as shown in Figure 4 (eg, the lower LVEF and the larger LVEDd at baseline, the greater the improvement in LVEF and LVEDd after HBP). When the patients with HBP were divided into 2 subgroups based on an LVEF: the HfPEF group with LVEF>40% and HFrEF group with LVEF≤40%, the percentage increase in LVEF (the ratio of LVEF at 1 year HBP over the baseline value) was 82.8±43.3% in HFrEF patients, which was significantly higher than that (14.0±24.4%) in HfPEF patients (P<0.001 versus the HfPEF group). In patients with HfPEF, both LVEDd and LVEF were improved at 3 months of HBP and further improved after 1 year of HBP (Table 2). In patients with HfPEF, there was no significant reduction in LVEDd after permanent HBP, whereas a significant improvement in LVEF was observed after 1 year of HBP (Table 2). Eleven patients with HFrEF received echocardiographic assessment ≈1 month (median 24 days) after the implementation of HBP. There was a moderate but significant improvement in LVEF during the acute phase of HBP, and the improvement continued further at 3 months and 1 year of HBP (Figure 5).

Clinical Outcomes After His Bundle Pacing

There was a significant overall reduction in the serum BNP concentration at the last follow-up (309.0±254.9 pg/mL) from the baseline concentration (531.9±468.5 pg/mL, P=0.019 versus the last follow-up). The BNP reduction after
HBP was different between HFrEF and HFpEF patients. At baseline, BNP concentration was significantly higher in HFrEF patients (726.0±367.7 pg/mL) than in HFpEF patients (298.2±212.2 pg/mL, \( P < 0.001 \) versus HFrEF patients). After 1 year of HBP, BNP concentration reduced to 148.3±232.4 pg/mL in HFrEF patients (\( P < 0.001 \) versus the baseline value), but there was no significant change in the HFpEF patients (308.5±254.1 pg/mL, \( P = 0.831 \) versus the baseline value). NYHA classification improved to 1.4±0.4 after 1 year of HBP from the baseline 2.9±0.6 in HFrEF patients (\( P < 0.001 \)) and to 1.4±0.5 after HBP from the baseline 2.7±0.6 in HFpEF patients (\( P < 0.001 \)).

During the follow-up period, 2 patients died (1 due to end-stage renal disease and the other during sleep of unknown cause), 1 patient had ventricular tachycardia terminated by antitachycardia pacing, and 2 patients experienced implant-related hospitalizations (1 for device replacement and 1 for minor pocket infection). All patients had at least 1 hospitalization for heart failure (hospitalization frequency 1.4±0.7 per patient) within 1 year before HBP, but only 2 patients (4.8%) had heart failure-related hospitalization within 12 months of HBP. When compared to the baseline values, the number of patients taking diuretics, β-blockers, and digoxin significantly decreased at 12 months of HBP, although the number of patients taking an angiotensin-converting enzyme inhibitor did not significantly change (Table 3). Of the 23 patients still on diuretics, 18 took diuretics at lower doses compared to baseline doses. The number of HFrEF patients taking diuretics decreased from 20 (100%) at baseline to 14 (70%) after HBP (\( P = 0.014 \) for reduction, Table 3), and the number of HFpEF patients taking diuretics decreased from 18 (81.8%) at baseline to 9 (40.9%) after HBP (\( P = 0.003 \) for the reduction, Table 3).

### Table 2. Comparison of the Echocardiographic Measurements at the Specific Time Points of HBP

|                  | LVEDd (mm) | P Value | LVEF (%) | P Value |
|------------------|------------|---------|----------|---------|
| **All patients (N=42)** |            |         |          |         |
| Baseline         | 55.8±8.1   | Ref.    | 44.9±14.6| Ref.    |
| 3 months         | 52.7±5.3   | 0.031   | 56.5±8.7 | <0.001  |
| 1 year           | 50.6±5.4   | <0.001  | 59.7±9.8 | <0.001  |
| Last FU          | 51.0±5.1   | <0.001  | 60.0±8.1 | <0.001  |
| **HFpEF patients (N=22)** |            |         |          |         |
| Baseline         | 51.5±5.4   | Ref.    | 56.6±9.9 | Ref.    |
| 3 months         | 50.2±4.4   | 0.385   | 60.1±8.0 | 0.231   |
| 1 year           | 49.0±4.4   | 0.073   | 63.2±8.2 | 0.010   |
| Last FU          | 49.6±3.9   | 0.159   | 62.6±6.9 | 0.019   |
| **HFrEF patients (N=20)** |            |         |          |         |
| Baseline         | 60.6±8.0   | Ref.    | 32.2±4.8 | Ref.    |
| 3 months         | 54.5±5.3   | 0.005   | 53.9±8.4 | <0.001  |
| 1 year           | 52.3±6.0   | <0.001  | 55.7±10.2| <0.001  |
| Last FU          | 52.6±5.9   | <0.001  | 57.2±8.7 | <0.001  |

P value is of specific time points of His bundle pacing vs the baseline by post hoc tests with least-significant difference. FU indicates follow-up; LVEDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; Ref., reference.

Figure 4. The Pearson product-moment correlation between echocardiographic changes in LVEDd and LVEF after HBP vs the baseline values. A, The correlation between the percentage change (ordinate, %) in LVEF after HBP over the baseline vs the baseline LVEF (abscissa). B, The percentage change (ordinate, %) in LVEDd after HBP over the baseline vs the baseline LVEDd (abscissa). HBP indicates His bundle pacing; LVEDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction.
Device Electrical Parameters During His Bundle Pacing at Follow-Up

Electrical data derived from implanted devices are summarized in a chronological order in Figure 6. Compared to the baseline, HBP thresholds did not significantly change during follow-up (Figure 6A). The percentage change in HBP thresholds at the last follow-up was 6.2±53.1% (median 0%) of baseline HBP thresholds. Five patients had an increase in HBP thresholds by at least 1 V over baseline thresholds (the range of the threshold increase was 1-1.35 V, and the range of baseline thresholds was 0.75-1.5 V). There was no statistically significant change in sensed R-wave amplitude (Figure 6B), and the percentage of HBP remained stable (Figure 6C). During the follow-up period, His-ventricular conduction remained intact without observation of exit block or progressive conduction delay.

Discussion

Major Findings

The present study utilized HBP after AVN ablation as a treatment for heart failure in AF patients with a narrow QRS complex and recent heart failure hospitalization despite heart rate control by medication. The study demonstrated that permanent HBP improved NYHA classification and reduced the use of diuretics for heart failure management in patients with either HFrEF or HFpEF. The echocardiographic measurements showed an improvement with a significant increase in LVEF and reduction in LVEDd, suggesting ventricular reverse remodeling, especially in HFrEF patients with lower baseline LVEFs. No serious adverse events, including lead dislodgement and exit block, were observed at implantation or during permanent HBP, demonstrating the safety and stability of HBP.

AVN ablation for AF requires permanent pacing. Options for pacing include pacing mode, such as RV pacing or biventricular pacing. Multiple clinical studies have demonstrated that long-term RV apical pacing can lead to cardiac dysfunction and heart failure deterioration.4-6 A major mechanism of the detrimental effect of RV apical pacing is due to ventricular dyssynchrony caused by abnormal ventricular activation.4,24 Cardiac resynchronization therapy is an option post–AVN ablation.25 However, several trials have failed to show a benefit of cardiac resynchronization therapy in patients with narrow QRS.19,20 Some degree of electrical dyssynchrony caused by biventricular pacing may be 1 potential mechanism.20 The present study applied permanent

Figure 5. Acute and long-term improvement in LVEDd (left) and LVEF (right) after His bundle pacing in patients with HFrEF. BL, baseline; 1M, 1 month after HBP; 3M, 3 months after HBP; 1Y, 1 year after HBP. Inserted P values were obtained by post hoc tests with least-significant difference. HBP indicates His bundle pacing; HFrEF, heart failure with reduced left ventricular ejection fraction; LVEDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction.

DOI: 10.1161/JAHA.116.005309
Table 3. Comparison of the Number of Patients Receiving Medications Before and 1 Year After HBP

|                      | Baseline | After HBP | P Value |
|----------------------|----------|-----------|---------|
| All patients (N=42)  |          |           |         |
| Diuretics            | 38 (90.5)| 23 (54.8) | <0.001  |
| β-Blockers           | 40 (95.2)| 32 (76.2) | 0.011   |
| ACE inhibitors       | 36 (85.7)| 38 (90.5) | 0.480   |
| Digoxin              | 20 (47.6)| 2 (4.8)   | <0.001  |
| HFrEF patients (N=20)|          |           |         |
| Diuretics            | 20 (100.0)| 14 (70.0) | 0.014   |
| β-Blockers           | 19 (95.0)| 18 (90.0) | 0.317   |
| ACE inhibitors       | 16 (80.0)| 19 (95.0) | 0.180   |
| Digoxin              | 13 (65.0)| 1 (5.0)   | <0.001  |
| HFpEF patients (N=22)|          |           |         |
| Diuretics            | 18 (81.8)| 9 (40.9)  | 0.003   |
| β-Blockers           | 21 (95.5)| 14 (63.6) | 0.020   |
| ACE inhibitors       | 20 (90.9)| 19 (86.4) | 0.564   |
| Digoxin              | 7 (31.8) | 1 (4.5)   | 0.034   |

Data were presented as N (%), and McNemar tests were performed to compare the differences between baseline and 1 year after HBP. ACE indicates angiotensin-converting enzyme; HBP, His bundle pacing; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

His Bundle Pacing in Heart Failure Patients

HBP in a subgroup of patients with heart failure who had recent heart failure hospitalizations even though medical therapy resulted in heart rate control during AF and patients had baseline narrow QRS complexes. HBP after AVN ablation in the present study not only provided heart rate control and rate regularization but also utilized the native His-Purkinje in the present study not only provided heart rate control and had baseline narrow QRS complexes. HBP after AVN ablation therapy resulted in heart rate control during AF and patients recent heart failure hospitalizations even though medical therapy provided heart rate control and had baseline narrow QRS complexes. HBP after AVN ablation was evidenced by a complete AV block without change in HBP parameters, including (1) no changes in HBP threshold and His-ventricular conduction time.

The present study demonstrated that performing AVN ablation and HBP implantation was safe and feasible. The AVN ablation site should be at least 8 mm away from the HBP site to avoid potential injury to the distal His bundle. The success of AVN ablation and HBP was evidenced by a complete AV block without change in HBP parameters, including (1) no changes in HBP threshold and His-ventricular conduction time.
and (2) the same morphology of QRS complex during HBP before and after AVN ablation. The present study demonstrated successful permanent HBP in 80.8% of all enrolled patients (96.2% patients had successful acute HBP), which was comparable to the success rate of HBP in previous investigations.12,15,17,18 During the median follow-up of 20 months in the present study, the overall HBP threshold remained relatively stable, and there was no observation of progressive His-ventricular conduction delay and exit block. Moreover, the present study did not observe serious adverse events related to implantation procedures, AVN ablation, or late lead dislodgement. Thus, our findings demonstrated that implantation procedures in conjunction with AVN ablation and permanent HBP are safe and stable.12-18

Figure 6. Electrical parameters of HBP and the percentage of HBP during the follow-up period. A, HBP threshold; (B) sensed R-wave amplitude; and (C) the percentage of HBP. BL indicates baseline value; W1, 1-week follow-up visit; M1, 1-month follow-up visit; M3, 3-month follow-up visit; M6, 6-month follow-up visit; Y1, 1-year follow-up visit; LFU, last follow-up visit. No significance (P>0.05) among different time points was detected by repeated-measures analysis of variance. HBP indicates His bundle pacing.
Observation of narrow QRS and underwent AVN ablation for AF. We observed a significant improvement in LVEF during the acute phase of HBP and a significantly greater improvement at 3 months and 1 year after HBP, suggesting that a long-term beneficial effect of HBP is present in addition to acute effects via ventricular rate and regularity control by HBP. Furthermore, the present study is limited by the small patient population studied. Thus, clinical benefits generated by permanent HBP in the present study should be confirmed in future large-scale clinical trials of diverse groups of heart failure patients with longer follow-up. Moreover, permanent HBP could not be achieved in some patients, and implantation procedures were longer and more complicated than RV apical lead implantation. Thus, strategies to prescreen patients for HBP and improvement in techniques to identify the His bundle region with a low and stable HBP threshold are needed.

Conclusion

The present study demonstrated that the permanent HBP is safe and stable in a population of heart failure patients who had narrow QRS and underwent AVN ablation for AF. We observed a significant improvement in NYHA classification and echocardiographic LVEF and LVEd and reduction in use of diuretics for heart failure treatment without an exit block and the development of progressive abnormality of His-ventricular conduction during a median 20-month follow-up of permanent HBP. Although the improvement after permanent HBP was present in patient groups with either HFrEF or HFrEF, randomized, controlled clinical trials with a larger sample size are needed to further confirm these findings before permanent HBP can be adopted as a standard practice for these patients.

Disclosures

None.

References

1. Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation. 1997;96:2617–2624.
2. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138–1144.
3. Marshall HJ, Harris ZI, Griffith MJ, Holder RL, Gammage MD. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation. 1999;99:1587–1592.
4. Verwooy K, Dijkman B, Cheriec EJ, Prinzen FW, Crijns HJ. Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol. 2006;97:1223–1227.
5. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutelek SP, Sharma A; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288:3115–3123.
6. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA; Mode Selection Trial Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–2937.
7. Saxon LA, De Marco T, Schaffer J, Chatterjee K, Kumar UN, Foster E; VIGOR Congestive Heart Failure Investigators. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation. 2002;105:1304–1310.
8. O’Keefe JH Jr, Abussa H, Jones PG, Thompson RC, Bateman TM, McAlpine AI, Ramza BM, Steinhaus DM. Effect of chronic right ventricular apical pacing on left ventricular function. Am J Cardiol. 2005;95:771–773.
9. Schoenfeld MH. Alternative site pacing to promote cardiac synchrony: has conventional pacing become unconventional? J Am Coll Cardiol. 2006;47:1946–1948.
10. Vardas PE, Simantirakis EN, Kansapakis EM. New developments in cardiac pacemakers. Circulation. 2013;127:2343–2350.
11. El-Sherif N, Amay-Y-Leon F, Schonfeld C, Scherlag BJ, Rosen K, Lazzara R, Wyndham C. Normalization of bundle branch block patterns by distal His bundle pacing. Clinical and experimental evidence of longitudinal dissociation in the pathologic His bundle. Circulation. 1978;57:473–483.
12. Deshmukh P, Casavant DA, Romanshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation. 2000;101:869–877.
13. Deshmukh PM, Romanshyn M. Direct His-bundle pacing: present and future. Pacing Clin Electrophysiol. 2004;27:862–870.
14. Barba-Pichardo R, Morina-Vazquez P, Fernandez-Gomez JM, Venegas-Gamero J, Herrera-Carranza M. Permanent His-bundle pacing: seeking physiological ventricular pacing. Europace. 2010;12:527–533.
15. Kronborg MB, Mortensen PT, Gerdes JC, Jensen HK, Nielsen JC. His and para-His pacing in AV block: feasibility and electrocardiographic findings. J Interv Card Electrophysiol. 2011;31:255–262.
16. Barba-Pichardo R, Manovel Sanchez A, Fernandez-Gomez JM, Morina-Vazquez P, Venegas-Gamero J, Herrera-Carranza M. Ventricular resynchronization therapy by direct His-bundle pacing using an internal cardioverter defibrillator. Europace. 2013;15:83–90.
17. Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015;12:305–312.
18. Lustgarten DL, Crespo EM, Arkipova-Jenkins I, Lobel R, Winget J, Koehler J, Liberman E, Sheldon T. His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: a crossover design comparison. Heart Rhythm. 2015;12:1548–1557.
Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. *N Engl J Med.* 2013;369:1395–1405.

20. Ploux S, Eschalier R, Whinnett ZI, Lumens J, Derval N, Haissaguerre M, Wilkoff BL, Francis DP, Bordachar P. Electrical dyssynchrony induced by biventricular pacing: implications for patient selection and therapy improvement. *Heart Rhythm.* 2015;12:782–791.

21. Wann LS, Curtis AB, January CT, Ellenbogen KA, Estes NA III, Page RL, Jacobs AK, Anderson JL, Albert N, Hochman JS, Brunskill OJ, Maseri A, O’Connell J, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Fuster V, Hylek EM, Rydén LE, Semigran MJ, Torbicki A; American College of Cardiology/American Heart Association/American College of Cardiology Foundation (Committee to Update the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2011;57:223–242.

22. Danik JS, Bulwer BE. Mitral regurgitation. In: Solomon SD, Bulwer B, eds. *Essential Echocardiography: A Practical Handbook With DVD.* Totowa, NJ: Humana Press; 2007:285–284.

23. Tops LF, Schalij MJ, Bax JJ. The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. *J Am Coll Cardiol.* 2009;54:764–776.

24. Curtis AB, Wiler MJ, Adamson PB, Chun ES, Niazi I, Sherfesees L, Shinn T, Sutton MS. Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med.* 2013;368:1585–1593.

25. Lustgarten DL, Calame S, Crespo EM, Calame J, Lobel R, Spector PS. Electrical resynchronization induced by direct His-bundle pacing. *Heart Rhythm.* 2010;7:15–21.

26. Heinz G, Siostrzzonek P, Kreiner G, Gossinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. *Am J Cardiol.* 1992;69:489–492.

27. Brignole M, Gianfranchi L, Menozzi C, Bottini N, Bollini R, Lolli G, Oddone D, Gaggeoli G. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. *Am J Cardiol.* 1994;74:242–246.

28. Kay GN, Ellenbogen KA, Giudici M, Redfield MM, Jenkins LS, Mianulli M, Wilkoff B. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. *AP Investigators. J Interv Card Electrophysiol.* 1998;2:121–135.

29. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McAlister RA, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hirst D, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Frobert O, Gersh BJ, Grossman W, Jaffe AS, Johnson WR, June CH, Manolis AJ, Maseri A, Nishimura RA, Oh JK, Ross JJ, Thygesen K, Torbicki A; American College of Cardiology/American Heart Association/American College of Cardiology Foundation/American College of Cardiology Foundation (Committee to Develop Guidelines on the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. *J Am Coll Cardiol.* 2001;38:1231–1266.

30. Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction: persistent diagnostic, therapeutic enigma. *Curr Cardiovasc Risk Rep.* 2011;5:440–449.

31. Cha YM, Wokhu A, Asirvatham SJ, Shen WK, Friedman PA, Munger TM, Oh JK, Monahan KH, Haroldson JM, Hodge DO, Herges RM, Hammill SC, Packer DL. Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a comparison to systolic dysfunction and normal ventricular function. *Circ Arrhythm Electrophysiol.* 2011;4:724–732.

32. Shan P, Su L, Chen X, Xu L, Xi X, Huang W. Direct His-bundle pacing improved left ventricular function and remodelling in a biventricular pacing nonresponder. *Can J Cardiol.* 2016;32:1577.e1–1577.e4.